|
Evaluation of the effectiveness of Persian Medicine product (Padzahr) in controlling
the symptoms of patients with COVID-19: A pilot study
|
Assie Jokar   , Ali Reza Davoudi , Fataneh Hashem Dabaghian , Gholamreza Kordafshari , Hoorieh Mohammadi Kenari * |
|
|
|
Abstract: (1340 Views) |
Background and Purpose: Coronaviruses, with single-stranded RNA, are widespread and cause respiratory, gastrointestinal, liver, and neurological diseases. This study aimed to evaluate the effect of Padzahr capsules to control clinical symptoms in patients with COVID-19 in a pilot clinical study.
Materials and Methods: This is a randomized controlled clinical trial study that was conducted in the summer and autumn of 1400 AD (2021) in Mazandaran province. The statistical population comprised COVID-19 patients based on the Iranian protocol and based on the set criteria. In this study, 68 definitive patients were randomly divided into intervention (Padzahr) and control groups. All patients admitted with COVID-19 in the infectious ward received routine corona treatment drugs, and the intervention group were additionally administered six Padzahr capsules per day (manufactured by NIAK with license number 0385-94). Data were analyzed by SPSS software (version: 17) using the ITT method. The criterion for statistical significance was a value of P less than 0.05.
Results: At the time of admission, there was no significant difference between the two groups in terms of severity of signs and symptoms (p> 0.05); The severity of signs and symptoms during hospitalization did not show a statistically significant difference. At 14-day follow-up, 28 patients in the drug group and 24 patients in the control group responded. Twenty-two patients (78.6%) in the drug group and 11 patients (45.8%) in the control group reported complete improvement of symptoms. No side effects were observed or reported in Padzahr users.
Conclusion: Padzahr caused a decrease in the severity of signs and symptoms of COVID-19 disease, but did not show a statistically significant difference compared to the control group during hospitalization. At follow-up two weeks later, the intervention group had better conditions and fewer symptoms. |
|
| Keywords: Persian Medicine, COVID-19, Acute Respiratory Syndrome |
|
|
Full-Text [PDF 54 kb]
|
Memorial article: Origianal Research |
Subject:
Special
Received: 2022/03/13 | Accepted: 2022/06/21
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
